| Name | Title | Contact Details |
|---|
Imagine a company with vision of fundamentally changing an industry, and the small design firms who dominate it, by empowering them to accelerate their growth and better their bottom lines. Its with intellectual capital, education programs, passion and strong relationship, that this small business is dedicated to developing a nationwide network of companies who are recognized by the industry as the most professional and by consumers as the best value in kitchen and bathrooms. Welcome to SEN. The SEN Design Group is the industrys first kitchen and bath buying and business development group. As a 26-year-old professional organization, SEN has over 210 members nationwide and more than 75 quality vendors in cabinetry, appliances, plumbing fixtures, decorative hardware, closets, lighting, bathroom products, flooring, tile, business services and accessories who offer their products/services to the membership at group rates. Additionally, SEN offers over 40 business development services to its membership, including financial planning, business coaching, business management training, sales training programs, marketing tools to generate leads, networking, and management systems. For more information on SEN visit www.sendesigngroup.com
Providing real-time asset tracking in any environment, with applications in manufacturing, defense, energy, inventory management, logistics, and security. WISERs ultra-wideband (UWB) system operates without line-of-sight and registers asset locations within inches in most cases.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Structure and develop real eastate and other hard asset deals.